Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2010

01-05-2010 | Urologic Oncology

The Diminishing Role of Transurethral Resection of the Prostate

Authors: Ray M. Merrill, PhD, MPH, Bradley D. Hunter, BA

Published in: Annals of Surgical Oncology | Issue 5/2010

Login to get access

Abstract

Background

This study provides an update of patterns in transurethral resection of the prostate (TURP) rates in the United States and the extent of TURP-detected prostate cancer incidence rates.

Methods

Analyses are based on data from the National Hospital Discharge Survey, the Surveillance, Epidemiology, and End Results Program, and the U.S. Census Bureau for the years 1996 through 2006.

Results

TURP procedure rates were 6, 14, and 18 times greater in men aged 60 to 69, 70 to 79, and ≥80 years compared with men aged 50 to 59, respectively. During 1996–2006, the estimated annual percentage change in TURP rates was −10.5 (95% confidence interval [95% CI] −14.1 to −6.7) for ages 50 to 59, −7.4 (95% CI −9.2 to −5.6) for ages 60 to 69, −6.2 (95% CI −7.6 to −4.8) for ages 70 to 79, and −7.7 (95% CI −9.5 to −5.8) for ages ≥80 years. TURP-detected prostate cancer incidence rates were 2, 7, and 17 times greater in men aged 60 to 69, 70 to 79, and ≥80 years compared with men aged 50 to 59, respectively. The estimated annual percentage change in trend was −17.8 (−20.6, −15.0) for ages 50 to 59, −14.8 (−16.6, −13.0) for ages 60 to 69, −10.8 (−12.0, −9.7) for ages 70 to 79, and −8.2 (−10.0, −6.5) for ages ≥80 years. Trends in prostate cancer incidence rates peaked in 2002 and decreased thereafter. Some of the decreasing trend in rates among older age groups is because of a decrease in TURPs and consequently a decrease in incidental TURP-detected cases.

Conclusions

TURP procedure rates and incidental TURP-detected prostate cancer incidence rates have declined and will likely continue to decline in the future.
Literature
1.
2.
Edwards CN, Steinthorsson E, Nicholson D. An autopsy of latent prostatic cancer. Cancer. 1953;6:531.CrossRefPubMed
3.
Hirst AE Jr, Bergman RT. Carcinoma of the prostate in men 80 or more years old. Cancer. 1954;7:136.CrossRefPubMed
4.
Whitmore WF Jr. Symposium of hormones and cancer therapy hormone therapy in prostatic cancer. Am J Med. 1956;21:295.
5.
Scott R Jr, Mutchnik DL, Laskowski TZ, et al. Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol. 1969;101:602.PubMed
6.
Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer. 1977;20:680–8.CrossRefPubMed
7.
Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–6.PubMed
8.
Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology. 2000;56:3–6.CrossRefPubMed
9.
Platz EA, Smit E, Curhan GC, et al. Prevalence of and racial/ethnic variation in lower urinary tract symptoms and noncancerprostate surgery in US men. Urology. 2002;59:877–83.CrossRefPubMed
10.
Trueman P, Hood SC, Nayak USL, et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed “benign prostatic hyperplasia,” and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83:410–15.CrossRefPubMed
11.
Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:495–507.PubMed
12.
Fitzpatrick JM. The natural history of benign prostate hyperplasia. BJU Int. 2006;97(Suppl 2):3–6.CrossRefPubMed
13.
Geller J. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab. 1990;71:1552–5.CrossRefPubMed
14.
Crea G, Sanfilippo G, Anastasi G, et al. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int. 2005;74:51–3.CrossRefPubMed
15.
Tacklind J, Fink HA, MacDonald R, et al. Finasteride for benign prostatic hyperplasia (Protocol). Cochrane Database Syst Rev. 2009;(3):CD006015.
16.
Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41.CrossRefPubMed
17.
Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–41.CrossRefPubMed
18.
Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. J Urol. 2005;173:515.
19.
Wilt T, MacDonald R, Hagerty K, et al. Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;(2):CD007091.
20.
Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement:2-year results from the CombAT study. J Urol. 2008;179:616–21.CrossRefPubMed
21.
Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin:3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. Eur Urol. 1999;36:609–20.CrossRefPubMed
22.
Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology. 1998;51:901–6.CrossRefPubMed
23.
Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995;76:325–36.CrossRefPubMed
24.
Narayan P. Tamsulosin: the United States trials. Geriatrics. 1998;53:S29–32.PubMed
25.
Chapple C, Andersson KE. Tamsulosin: an overview. World J Urol. 2002;19:397–404.PubMed
26.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet. 1991;337(8755):1457–61.CrossRefPubMed
27.
Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month survey. Br J Urol. 1994;74:579–84.CrossRefPubMed
28.
Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2001;58:953–9.CrossRefPubMed
29.
Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet. 1991;338(8760):182.
30.
Vallancien G, Emberton M, Alcaraz A, et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int. 2008;101:847–52.CrossRefPubMed
31.
McVary KT. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience. J Urol. 2006;175:35–42.CrossRefPubMed
32.
Takao T, Tsujimura A, Kiuchi H, et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol. 2008;15:992–6.PubMed
33.
Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019–24.CrossRefPubMed
34.
Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181:2634–40.CrossRefPubMed
35.
Merrill RM, Feuer EJ, Warren JL, et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol. 1999;150:848–60.PubMed
36.
Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948–54.CrossRefPubMed
37.
Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–52.CrossRefPubMed
38.
Merrill RM, Potosky AL, Feuer EJ. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst. 1996;88:1683–5.CrossRefPubMed
39.
40.
National Center for Health Statistics. National Hospital Discharge Survey Annual Summary, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006 (machine-readable data file and documentation). Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2007.
41.
Ries LAG, Kosary CL, Hankey BF, et al., editors. SEER Cancer Statistics Review, 1973–94. NIH Pub. No. 97-2789. Bethesda, MD: National Cancer Institute; 1997.
42.
43.
Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence—SEER 13 Regs Limited-Use, Nov 2008 Sub (1992–2006) Katrina/Rita Population Adjustment—Linked to County Attributes—Total US, 1969–2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. Available at: http://​www.​seer.​cancer.​gov. Accessed July 24, 2009.
44.
Kleinbaum DG, Kupper LL, Muller KE 1988 Applied Regression Analysis of Other Multivariable Methods. North Scituate, MA: Duxbury Press, pp 266–8.
45.
US Department of Health and Human Services. International Classification of Diseases, Ninth Revision. Clinical modification (ICD-9-CM). 3rd ed. DHHS Publication No. (PHS) 89-1260. Hyattsville, MD: US Department of Health and Human Services; 1989.
46.
47.
Jones JS, Follis HW, Johnson JR. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era. Prostate Cancer Prostatic Dis. 2009;12:57–60.CrossRefPubMed
48.
Hoffman RM, Monga M, Elliot SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007;(4):CD004135.
49.
50.
51.
Boyle P, Robertson C, Vaughan ED. A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int. 2004;94:83–8.CrossRefPubMed
52.
Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–52.CrossRefPubMed
53.
Etzioni R, Gulati R, Falcon S, et al. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making. 2008;28:323–31.CrossRefPubMed
Metadata
Title
The Diminishing Role of Transurethral Resection of the Prostate
Authors
Ray M. Merrill, PhD, MPH
Bradley D. Hunter, BA
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 5/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0896-4

Other articles of this Issue 5/2010

Annals of Surgical Oncology 5/2010 Go to the issue

Breast Oncology

Metastatic Potential of T1 Breast Cancer can be Predicted by the 70-gene MammaPrint Signature

Breast Oncology

Topoisomerase 2 Alpha and the Case for Individualized Breast Cancer Therapy

Colorectal Cancer

High Level of Notch1 Protein is Associated with Poor Overall Survival in Colorectal Cancer

EDUCATIONAL REVIEW – EMERGING THERAPEUTIC APPROACHES TO HEPATOCELLULAR CARCINOMA

Emerging Therapeutic Approaches to Hepatocellular Carcinoma

EMERGING THERAPEUTIC APPROACHES TO HEPATOCELLULAR CARCINOMA

Systemic Treatment of Hepatocellular Carcinoma: Dawn of a New Era?

Gastrointestinal Oncology

Advanced Gastric Cancer with Early Cancer Macroscopic Appearance: Is It Worthy of D2 Lymphadenectomy?